Metabolic Syndrome

Abstract

Metabolic syndrome is a clustering of cardiovascular risk factors that consists of abdominal obesity, hypertension, atherogenic dyslipidemia, hyperglycemia, and prothrombotic and proinflammatory conditions; furthermore, this syndrome is a major risk factor for the development of type 2 diabetes and atherosclerotic cardiovascular diseases. Metabolic syndrome prevalence is increasing every year in our country and in the world. Vascular disease (peripheral, cardiac and cerebral) because of metabolic syndrome is important cause of morbidity and mortality.

Keywords

• Metabolic Syndrome, diagnosis, therapy

Metabolik Sendrom

Öz

Özet: Metabolik sendrom abdominal obezite, hipertansiyon,aterojenik dislipidemi, hiperglisemi, protrombotik veproinflamatuvar durumlarla karakterize bir kardiyometabolikrisk faktörleri demetidir ve tip 2 diyabet ve aterosklerotikkardiyovasküler hastalık gelişimi için önemli bir riskfaktörüdür Metabolik sendrom sıklığı dünyada, ve ülkemizdesıklığı artan,özellikle oluştuduğu vasküler hastalıklar nedeniile morbidite ve mortalitede önemli etkileri olan bir tablodur.

Anahtar Kelimeler

• Metabolik sendrom,teşhis,tedavi

Kaynakça

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
3. Reaven GM. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988.
4. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-36.
5. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295300.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356-9.
7. Kozan Ö, Oğuz A, Abacı A, Erol C, Öngen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr. 2007;61:548-53.
8. Mehmet Ali Nahit Şendur, Gülay Sain Güven , Metabolik Sendroma Güncel Bakış, İç Hastalıkları Dergisi 2011; 18: 125-1 cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.

9. Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22.
10. Jacob S, Henriksen EJ. Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2004;6:690-6.
11. Gleiter CH, Jägle C, Gresser U, Mörike K.Candesartan. Cardiovasc Drug Rev 2004;22: 263-84.
12. Hansson L, Zanchetti A, Carruthers SG,Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive bloodpressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62
13. Oğuz A, Altuntaş Y, Karsidağ K, Güleç S, Temizhan A, Akalın AA, et al. The prevalence of metabolic syndrome in Turkey. Obesity Reviews 2010; 11: 486.
14. Gören B ,Fen T, Metabolik Sendrom, Turkiye Klinikleri J Med Sci 2008;28:686-696